Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility

Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016

Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab

Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences

Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers

Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab

Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015